|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||13.06 / 47.98|
Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.
Mylan shares were indicated sharply higher Monday amid reports the generic drugs group is set to create a separate business with Pfizer for off-patent pharmaceuticals.
- As previously announced, BRAFTOVI combinations showed statistically significant improvement in OS and ORR versus control -
Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.
Watch the Russell 2000, housing activity, and mergers and acquisitions.
NEW YORK, June 27, 2019 /PRNewswire/ -- Array BioPharma Inc. (ARRY) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the proposed sale of ARRY to Pfizer, Inc.
The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.
The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.
BOULDER, Colo., June 25, 2019 /PRNewswire/ -- Array BioPharma Inc.
NEW YORK, June 21, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating: BioScrip, Inc.
The names include a veterinary drug concern plus companies with successful drugs on the market.
These two firms have successful drugs and could make nice additions for larger companies.
NEW YORK, June 18, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Array BioPharma ("Array" or the "Company") (NASDAQ: ARRY) in connection with the proposed...
Stocks end moderately ahead as investors are adopting a cautious stance heading into this week's Federal Reserve meeting.
I'm inclined to add to Disney on today's weakness.
Pfizer said Monday it has agreed to acquire Array Biopharma in an all-cash deal that values the cancer drug specialist at around $11.4 billion.
- Proposed acquisition strengthens Pfizer's innovative biopharmaceutical business and is expected to accelerate its growth trajectory particularly in the long term
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.
A roundup of Jim Cramer's thoughts on stocks of interest to Mad Money viewers.
Key oscillator signal works again, but that's no reason to nod off, Jim Cramer says.
BOULDER, Colo., June 4, 2019 /PRNewswire/ -- Array BioPharma Inc.
BOULDER, Colo., May 29, 2019 /PRNewswire/ -- Array BioPharma Inc.
- Consistent with prior readouts, BRAFTOVI + MEKTOVI demonstrates 33.6 months median overall survival with longer median follow up over 48 months -
- BRAFTOVI combinations showed statistically significant improvement in ORR and OS versus control -
BOULDER, Colo., May 9, 2019 /PRNewswire/ -- Array BioPharma Inc.
- Net product sales of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in U.S. were $35.1 million in the third quarter -
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.